Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Efficacy and safety of rilonacept (interleukin-1 Trap) in patients with cryopyrin-associated periodic syndromes: results from two sequential placebo-controlled studies.

Arthritis and rheumatism - 1 Aug 2008

Hoffman Hal M, Throne Martin L, Amar N J, Sebai Mohamed, Kivitz Alan J, Kavanaugh Arthur, Weinstein Steven P, Belomestnov Pavel, Yancopoulos George D, Stahl Neil, Mellis Scott J

Abstract excerpt

OBJECTIVE: To assess the efficacy and safety of rilonacept (Interleukin-1 [IL-1] Trap), a long-acting and potent inhibitor of IL-1, in patients with cryopyrin-associated periodic syndromes (CAPS), including familial cold autoinflammatory syndrome (FCAS) and Muckle-Wells syndrome (MWS). METHODS: Forty-seven adult patients with CAPS, as defined by mutations in the causative NLRP3 (CIAS1) gene and pathognomonic...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Arthralgia
Share to Familial Mediterranean Fever

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Immunoglobulin Fc Fragments

Share to Injections, Subcutaneous

Share to NLR Family, Pyrin Domain-Containing 3 Protein

Share to Receptors, Interleukin-1

Share to Serum Amyloid A Protein

Share to Single-Blind Method

Source

Identifiers

PMID: 18668535
DOI: 10.1002/art.23687

Genes

CAPS
NLRP3

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Efficacy and safety of rilonacept (interleukin-1 Trap) in patients with cryopyrin-associated periodic syndromes: results from two sequential placebo-controlled studies.PMID 18668535Read ↗

A pilot study to evaluate the safety and efficacy of the long-acting interleukin-1 inhibitor rilonacept (interleukin-1 Trap) in patients with familial cold autoinflammatory syndrome.Semantic proximity Read ↗

Cryopyrin-associated periodic syndromes: background and therapeuticsSemantic proximity Read ↗

Pharmacological treatment options for cryopyrin-associated periodic syndromes.Semantic proximity Read ↗

[CAPS: cryopyrin-associated periodic syndrome].Semantic proximity Read ↗

Cryopyrin-associated periodic syndromes: diagnosis and management.Semantic proximity Read ↗

Current treatment recommendations and considerations for cryopyrin-associated periodic syndrome.Semantic proximity Read ↗

Impact of IL-1 inhibition on fatigue associated with autoinflammatory syndromes.Semantic proximity Read ↗

Cryopyrin-associated periodic syndrome: an update on diagnosis and treatment response.Semantic proximity Read ↗

Guidelines for the management and treatment of periodic fever syndromes: Cryopyrin-associated periodic syndromes (cryopyrinopathies - CAPS).Semantic proximity Read ↗

Refining treat-to-target strategies in cryopyrin-associated periodic syndromes: the role of inflammatory markers.Semantic proximity Read ↗

CAPS--pathogenesis, presentation and treatment of an autoinflammatory disease.Semantic proximity Read ↗

AA amyloidosis complicating cryopyrin-associated periodic syndrome: a study of 86 cases including 23 French patients and systematic review.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.